Publications Database

Baxter A. , Krenzelok E. (2008)

Pediatric fatality secondary to EDTA chelation.

Clin Toxicol (Phila).

46(10), pp. 1083-1084

Read Abstract (New Window) Read Full (New Window)

Bent S. , Hendren. R. L. (2010)

Improving the prediction of response to therapy in autism.

Neurotherapeutics

7(3), pp. 232-240

Read Abstract (New Window)

Bent S. , Bertoglio K. , Hendren. R. L. (2009)

Regarding omega-3 fatty acids in severe autism.

Archives of Medical Research

40(1), pp. 64

Black S. L. et al. (1994)

Naltrexone in infantile autism.

Journal of Autism and Developmental Disorders

24(2), pp. 236-239

Read Extract (New Window)

Boris N. W. (2003)

Attachment, aggression and holding: a cautionary tale.

Attachment and Human Development

5(3), pp. 245-247.

Bovee J. (2000)

A right to our own life, our own way.

Focus on Autism and Other Developmental Disabilities

15(4), pp. 250-252

Read Abstract (New Window)

Brent J. (2013)

Commentary on the abuse of metal chelation therapy in patients with autism spectrum disorders.

Journal of Medical Toxicology

9(4), pp. 370-372.

Read Abstract (New Window)

Broderick A. (2009)

Autism, 'recovery (to normalcy)', and the politics of hope.

Journal of Intellectual and Developmental Disability

47(4), pp. 263-281

Read Abstract (New Window)

Brownlow C. (2010)

Re-presenting autism: The construction of 'NT Syndrome'.

Journal of Medical Humanities

31(3), pp. 243-255.

Read Abstract (New Window)

Brudnak M. A. (2001)

Application of genomeceuticals to the molecular and immunological aspects of autism.

Medical Hypotheses

57(2), pp. 186-191

Read Abstract (New Window)

Burd L. , Fisher W. W. , Kerbeshian J. (1989)

Pervasive disintegrative disorder: Are Rett syndrome and Hellers dementia infantalis subtypes?

Developmental Medicine and Child Neurology

31(5), pp. 609-616.

Read Abstract (New Window)

Caldwell R. L. et al. (2012)

The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.

Research in Autism Spectrum Disorders

August, 22(4), pp. 277-283.

Read Abstract (New Window) Read Full (New Window)

Canitano R. (2013)

Novel treatments in autism spectrum disorders: from synaptic dysfunction to experimental therapeutics.

Behavioural Brain Research

251 pp. 125-132.

Read Abstract (New Window)

Careaga M. , Van de Water J. , Ashwood P. (2010)

Immune dysfunction in autism: A pathway to treatment.

Neurotherapeutics

7(3), pp. 283-292

Read Abstract (New Window)

Carlson L. (2013)

Research ethics and intellectual disability: broadening the debates.

Yale Journal of Biology and Medicine

September, 86(3), pp. 303-301.

Read Abstract (New Window) Read Full (New Window)

Carr J. E. , Firth A. M. (2005)

The verbal behavior approach to early and intensive behavioral intervention for autism: A call for additional empirical support.

Journal of Early and Intensive Behavior Intervention

2(1), pp.18-27.

Read Full (New Window)

Cashin A. , Barker P. (2009)

The triad of impairment in autism revisited.

Journal of Child and Adolescent Psychiatric Nursing

22(4), pp. 189-193

Read Abstract (New Window)

Chew K. L. , Iacono T. , Tracy J. (2009)

Overcoming communication barriers: working with patients with intellectual disabilities.

Australian Family Physician

38(1),

Read Abstract (New Window) Read Full (New Window)

Coben R. , Ricca R. (2015)

EEG biofeedback for autism spectrum disorder: A commentary on Kouijzer et al. (2013).

Applied Psychophysiological and Biofeedback

March, 40(1), pp. 53-56.

Read Abstract (New Window)

Corbett B. A. (2016)

Autism, art, and accessibility to theater.

AMA Journal of Ethics

18(12), pp. 1232-1240.

Read Abstract (New Window) Read Full (New Window)